國家衛生研究院 NHRI:Item 3990099045/2979
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 857839      在线人数 : 835
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/2979


    题名: A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy
    作者: Chen, YM;Perng, RP;Tsai, CM;Whang-Peng, J
    贡献者: National Institute of Cancer Research
    摘要: Both gemcitabine and UFUR (UFT, tegafur/uracil) are effective agents against chemo-naive non-small-cell lung cancer (NSCLC). Their effectiveness in patients failing previous chemotherapy is uncertain. Our aim was to evaluate the efficacy of gemcitabine plus UFUR in NSCLC patients who failed previous platinum-based chemotherapy. Forty-five patients were enrolled. The performance status was 1 in 29 patients and 2 in 16 patients. Treatment consisted of gemcitabine 1000 mg/m(2) intravenous infusion on days 1 and 8, plus oral UFUR 200 mg/m(2)/day from days 1 to 14 of every 3 weeks, to a maximum of six cycles, carried out in the outpatient clinic. One hundred and sixty cycles of treatment were given (mean 3.6 cycles per patient). Grade 3 or 4 toxicities included anemia in four patients, leukopenia in three patients, neutropenia in eight patients, thrombocytopenia in four patients, and fatigue in two patients. After two cycles of treatment, seven of 45 patients (15.6%) had a partial response. The median survival was 13.2 months. Survival was better in those with a better performance status (p = 0.0006), in those with disease control using the present treatment (p < 0.0001), and in those who received Iressa or Tarceva as salvage therapy after failing the present treatment (p = 0.0054). In conclusion, salvage chemotherapy using gemcitabine plus UFUR is active, easy to use, and well tolerated in NSCLC patients who have failed previous chemotherapy. Further treatment with EGFR-TKI is also suggested when patients fait the present treatment. C) 2006 Elsevier Ireland Ltd. All rights reserved.
    关键词: Oncology;Respiratory System
    日期: 2006-06
    關聯: Lung Cancer. 2006 Jun;52(3):333-338.
    Link to: http://dx.doi.org/10.1016/j.lungcan.2006.01.015
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0169-5002&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000238048300011
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33646364540
    显示于类别:[彭汪嘉康(1996-2007)] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    000238048300011.pdf145KbAdobe PDF957检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈